Presidential Symposium I

LINK to Presidential Symposium I 

LINK to STREAM (needs an ESMO registration)

LBA1 - Osimertinib adjuvant therapy in patients (pts) with resected EGFR mutated (EGFRm) NSCLC (ADAURA): Central nervous system (CNS) disease recurrence

The abstract concludes: There was a clinically meaningful improvement in CNS DFS with osimertinib: 82% reduction in risk of CNS disease recurrence or death. Results support that osimertinib reduces risk of CNS recurrence in the resected EGFRm NSCLC setting.


Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer

Y.‑L. Wu and Others


LBA2 - Lorlatinib vs crizotinib in the first-line treatment of patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC): Results of the phase III CROWN study

The abstract concludes: Lorlatinib resulted in a statistically significant and clinically meaningful improvement in PFS vs crizotinib and should be considered a new first-line treatment option for pts with ALK+ NSCLC.

Read also ESMO's Daily Reporter News: 

CROWN Trial Supports Lorlatinib as a Future First-line Standard Treatment in ALK-positive Non-small Cell Lung Cancer


696O_PR - Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial  

The abstract concludes: N+C demonstrated superior PFS, OS, and ORR v S in 1L aRCC. The safety profile of this combination was manageable and consistent with the known singleagent AE profiles of N and C. These results support N+C as a new CPI+TKI option for aRCC pts.